Zovighian said the transition to CEO has been relatively smooth since he joined Edwards in 2015 and spent eight years in ...
Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...
Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...
Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...
4d
Zacks.com on MSNShould Edwards Lifesciences Stock Remain in Your Portfolio Now?EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.
As the company faces headwinds in its core Transcatheter Aortic Valve Replacement (TAVR) business, it simultaneously sees promising growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT ...
37,249 people played the daily Crossword recently. Can you solve it faster than others?37,249 people played the daily Crossword recently. Can you solve it faster than others? EXCLUSIVE: John Goodman ...
Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...
Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results